Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pooled Mutant KRAS-Targeted Long Peptide Vaccine

Vaccine (Peptide vaccine) · Immune activation, directed at KRAS G12D, KRAS G12R and KRAS G12V

Phase 1/2 Most advanced trial

1 Registered trials

What is Pooled Mutant KRAS-Targeted Long Peptide Vaccine?

mKRASvax is a cancer vaccine containing synthetic long peptides targeting six KRAS mutations (G12D, G12R, G12V, G12A, G12C, G13D) combined with the adjuvant poly-ICLC. It stimulates cytotoxic T-lymphocyte responses against tumor cells expressing these KRAS mutations. The vaccine is being studied in pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: mKRASvax
Drug type: Vaccine (Peptide vaccine)
Targets: KRAS G12D (antigen), KRAS G12R (antigen), KRAS G12V (antigen), KRAS G12A (antigen), KRAS G12C (antigen), KRAS G13D (antigen)
Mechanism: Immune activation, directed at KRAS G12D, KRAS G12R and KRAS G12V
Pathways: immune activation
Therapy area: Oncology
In trials of: AGEN
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06782932	Phase 1/2	Pancreatic Cancer	Recruiting	AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic Cancer

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z